Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMT002
MIFTS: 62

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hematologic Cancer

About this section

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 12 54 15 37
Hematologic Neoplasm 12 29 6
Hematologic Malignancies 54 15
Hematologic Neoplasms 43 71
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematopoietic Neoplasms 71
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2531
MeSH 43 D019337
NCIt 49 C27134
UMLS 71 C0376544 C0376545 C3890429
Sources

Summaries for Hematologic Cancer

About this section
Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to bone marrow cancer and mast cell neoplasm. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Ceftazidime and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Sources

Related Diseases for Hematologic Cancer

About this section

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 869, show less)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.8 U2AF1 MPL MIR199A1 KIT JAK2 IL3
2 mast cell neoplasm 33.2 U2AF1 KIT IL3 IL2
3 8p11 myeloproliferative syndrome 33.1 RUNX1 KIT FLT3
4 leukemia, acute myeloid 33.1 U2AF1 RUNX1 NUP98 MPL MIR199A1 KMT2A
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.0 RUNX1 KMT2A KIT FLT3 ETV6
6 myeloma, multiple 32.6 U2AF1 PVT1 PTHLH MIR199A1 KIT JAK2
7 leukemia, acute lymphoblastic 32.5 XIST U2AF1 RUNX1 PTHLH MPL KMT2A
8 leukemia 32.5 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
9 myelodysplastic syndrome 32.5 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
10 leukemia, chronic lymphocytic 32.4 U2AF1 MIR199A1 KMT2A KIT JAK2 IL2
11 myeloid leukemia 32.3 U2AF1 RUNX1 NUP98 KMT2A KIT JAK2
12 lymphoma, non-hodgkin, familial 32.3 U2AF1 MIR199A1 KMT2A JAK2 IL3 IL2
13 lymphocytic leukemia 32.3 RUNX1 KMT2A IL3 IL2 ETV6 ABL1
14 blood platelet disease 32.3 U2AF1 RUNX1 MPL KIT JAK2 IL3
15 deficiency anemia 32.2 U2AF1 MPL JAK2 IL3 FLT3 CSF3
16 acute leukemia 32.2 RUNX1 NUP98 KMT2A KIT JAK2 IL3
17 aplastic anemia 32.2 U2AF1 MPL IL3 IL2 FLT3 CSF3
18 leukemia, chronic myeloid 32.1 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
19 lymphoma, hodgkin, classic 32.0 PVT1 JAK2 IL3 IL2 CSF3
20 refractory anemia 32.0 RUNX1 MPL IL3 CSF3
21 monocytic leukemia 31.9 RUNX1 KMT2A FLT3
22 leukemia, acute monocytic 31.8 U2AF1 NUP98 KMT2A FLT3
23 juvenile myelomonocytic leukemia 31.8 U2AF1 RUNX1 KMT2A JAK2 FLT3 CBL
24 thrombocytopenia 31.8 U2AF1 RUNX1 MPL JAK2 IL3 IL2
25 myeloid sarcoma 31.8 KMT2A KIT FLT3
26 myelofibrosis 31.8 U2AF1 RUNX1 MPL KIT JAK2 IL3
27 mastocytosis 31.7 KIT JAK2 IL3 FLT3 CBL
28 myeloproliferative neoplasm 31.7 U2AF1 RUNX1 MPL KMT2A KIT JAK2
29 chronic myelomonocytic leukemia 31.6 U2AF1 RUNX1 NUP98 MPL KIT JAK2
30 severe combined immunodeficiency 31.5 KIT IL3 IL2 FLT3 CSF3
31 thrombocytosis 31.5 U2AF1 MPL JAK2 IL3 CSF3
32 acute t cell leukemia 31.5 U2AF1 FLT3 ABL1
33 acute promyelocytic leukemia 31.5 RUNX1 PVT1 NUP98 KMT2A IL3 FLT3
34 stomatitis 31.4 NUP98 IL2 CSF3
35 precursor t-cell acute lymphoblastic leukemia 31.4 NUP98 KMT2A FLT3 ETV6 ABL1
36 severe congenital neutropenia 31.4 JAK2 IL3 IL2 FLT3 CSF3
37 myelodysplastic/myeloproliferative neoplasm 31.4 U2AF1 KMT2A JAK2 FLT3 ETV6 CBL
38 megakaryocytic leukemia 31.4 U2AF1 RUNX1 KMT2A JAK2 IL3
39 polycythemia vera 31.4 MPL KIT JAK2 IL3 ETV6 CSF3
40 pancytopenia 31.3 U2AF1 RUNX1 MPL KMT2A KIT IL3
41 essential thrombocythemia 31.3 U2AF1 MPL KIT JAK2 IL3 CSF3
42 paraneoplastic syndromes 31.3 PTHLH CSF3
43 mucositis 31.3 IL3 IL2 CSF3
44 chronic eosinophilic leukemia 31.3 U2AF1 KIT JAK2 FLT3 ETV6 ABL1
45 neutrophilia, hereditary 31.3 U2AF1 PTHLH JAK2 IL3 FLT3 CSF3
46 exanthem 31.3 KIT IL2 FLT3 CSF3
47 gastrointestinal stromal tumor 31.2 KIT JAK2 FLT3 CCDC26 CBL ABL1
48 thyroid gland cancer 31.2 U2AF1 PVT1 MIR199A1 KIT FLT3 ABL1
49 leukemia, acute lymphoblastic 3 31.2 RUNX1 KMT2A FLT3 ETV6 ABL1
50 chronic leukemia 31.2 U2AF1 KIT JAK2 FLT3 ABL1
51 childhood leukemia 31.2 RUNX1 KMT2A ETV6 CSF3 ABL1
52 renal cell carcinoma, nonpapillary 31.1 PVT1 PTHLH MIR199A1 KIT IL2 FLT3
53 polycythemia 31.1 MPL JAK2 IL3 ABL1
54 sm-ahnmd 31.1 U2AF1 KIT JAK2
55 wilms tumor 1 31.1 U2AF1 KMT2A KIT FLT3
56 mature b-cell neoplasm 31.0 U2AF1 PVT1 MIR199A1 IL2
57 pancreatic adenocarcinoma 31.0 U2AF1 KIT JAK2 IL2 CSF3
58 retinitis pigmentosa and erythrocytic microcytosis 31.0 JAK2 IL3 CSF3
59 hypereosinophilic syndrome 30.9 KIT JAK2 IL3 IL2 ABL1
60 acute myeloblastic leukemia with maturation 30.9 KIT FLT3
61 extracutaneous mastocytoma 30.8 U2AF1 KIT
62 hairy cell leukemia 30.8 U2AF1 IL3 IL2
63 acquired polycythemia 30.6 MPL JAK2
64 small cell cancer of the lung 30.5 U2AF1 KIT CSF3
65 central nervous system hematologic cancer 12.5
66 refractory hematologic cancer 12.5
67 obsolete: hereditary thrombocytopenia-hematological cancer predisposition syndrome 12.3
68 systemic mastocytosis with associated hematologic neoplasm 12.3
69 myeloproliferative/lymphoproliferative neoplasms, familial 11.9
70 mismatch repair cancer syndrome 11.7
71 adult t-cell leukemia 11.5
72 fusariosis 11.5
73 peripheral t-cell lymphoma 11.5
74 thrombocytopenia 5 11.5
75 lymphoma 11.5
76 platelet disorder, familial, with associated myeloid malignancy 11.3
77 ras-associated autoimmune leukoproliferative disorder 11.3
78 blood coagulation disease 11.3 U2AF1 MPL KIT JAK2 IL3 IL2
79 core binding factor acute myeloid leukemia 11.2 RUNX1 KIT JAK2 FLT3 CSF3 CBL
80 atypical chronic myeloid leukemia 11.2 U2AF1 RUNX1 PTHLH JAK2 ETV6 ABL1
81 primary polycythemia 11.2 U2AF1 MPL JAK2 IL3 FLT3 ABL1
82 rothmund-thomson syndrome, type 2 11.2
83 anemia, sideroblastic, 1 11.2
84 surfactant metabolism dysfunction, pulmonary, 4 11.2
85 mikulicz disease 11.2
86 scleredema adultorum 11.2
87 sideroblastic anemia 11.2
88 paroxysmal cold hemoglobinuria 11.2
89 cebpa-associated familial acute myeloid leukemia 11.1 RUNX1 KIT JAK2 FLT3 ETV6
90 chronic neutrophilic leukemia 11.1 U2AF1 KMT2A JAK2 CSF3 ABL1
91 pulmonary alveolar proteinosis, acquired 11.1
92 central nervous system leukemia 11.1
93 central nervous system lymphoma 11.1
94 histiocytic and dendritic cell cancer 11.1
95 refractory hairy cell leukemia 11.1
96 acquired pure red cell aplasia 11.1
97 leukocyte disease 11.1 U2AF1 MIR199A1 KIT IL2 CSF3
98 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 11.1 KIT JAK2 ETV6 ABL1
99 myelophthisic anemia 11.1 U2AF1 MPL JAK2 ABL1
100 amegakaryocytic thrombocytopenia, congenital 11.1 U2AF1 MPL JAK2 IL3
101 peripheral nervous system neoplasm 11.0 U2AF1 MIR199A1 KIT IL2
102 chromosome 5q deletion syndrome 11.0
103 necrobiotic xanthogranuloma 11.0
104 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.0 RUNX1 KIT FLT3
105 mental retardation, autosomal dominant 33 11.0 JAK2 ETV6 ABL1
106 tonsil cancer 11.0 MIR199A1 KIT ETV6
107 hepatic vascular disease 11.0 MIR199A1 JAK2 CSF3
108 lymphatic system cancer 10.9 KIT IL2 CSF3
109 testicular disease 10.9 MIR199A1 KIT IL2
110 uveal disease 10.9 U2AF1 MIR199A1 IL2
111 ring chromosome 21 10.9 KMT2A ETV6
112 lymphatic system disease 10.9 U2AF1 KIT IL2
113 large cell carcinoma 10.9 PTHLH KIT ABL1
114 cytogenetically normal acute myeloid leukemia 10.9 KMT2A FLT3
115 erythrocytosis, familial, 1 10.9
116 temporal arteritis 10.9
117 fanconi anemia, complementation group a 10.9
118 mycosis fungoides 10.9
119 poikiloderma with neutropenia 10.9
120 lymph node cancer 10.9
121 dyskeratosis congenita 10.9
122 erdheim-chester disease 10.9
123 monoclonal gammopathy of uncertain significance 10.9
124 sezary's disease 10.9
125 clpb deficiency 10.9
126 b cell prolymphocytic leukemia 10.9
127 bone marrow necrosis 10.9
128 primary agammaglobulinemia 10.9
129 vasculitis syndromes of the central and peripheral nervous systems 10.9
130 atopic keratoconjunctivitis 10.8 IL3 IL2
131 liver leiomyoma 10.8 KIT IL3
132 co-trimoxazole allergy 10.8 KIT CSF3
133 neutropenia, severe congenital, 3, autosomal recessive 10.8 IL3 CSF3
134 hypereosinophilic syndrome, idiopathic 10.8 KIT IL3
135 lymphoblastic leukemia, acute, with lymphomatous features 10.8 JAK2 ABL1
136 dysgerminoma of ovary 10.8 PTHLH KIT
137 testicular leukemia 10.7 ETV6 ABL1
138 diamond-blackfan anemia 10.6 U2AF1 MPL JAK2 IL3
139 t-cell leukemia 10.5
140 mucormycosis 10.4
141 hepatic veno-occlusive disease 10.4
142 candidiasis 10.4
143 colon leiomyoma 10.4 KMT2A KIT
144 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4
145 autoimmune disease 10.4
146 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.3
147 cutaneous t cell lymphoma 10.3
148 granulocytopenia 10.3
149 pneumonia 10.3
150 lymphopenia 10.3
151 neuropathy 10.3
152 splenomegaly 10.3
153 cytomegalovirus infection 10.3
154 hyperuricemia 10.2
155 acute kidney failure 10.2
156 peripheral nervous system disease 10.2
157 lymphoproliferative syndrome 10.2
158 cytokine deficiency 10.2
159 marginal zone b-cell lymphoma 10.2
160 constipation 10.2
161 herpes simplex 10.2
162 retinoblastoma 10.2
163 familial retinoblastoma 10.2
164 cll/sll 10.2
165 chickenpox 10.2
166 acute monoblastic leukemia 10.2
167 encephalopathy 10.2
168 b-cell lymphoma 10.1
169 hemophagocytic lymphohistiocytosis 10.1
170 hemosiderosis 10.1
171 47,xyy 10.1
172 stenotrophomonas maltophilia infection 10.1
173 immune deficiency disease 10.1
174 hepatitis c 10.1
175 hemolytic anemia 10.1
176 amyloidosis 10.1
177 alopecia 10.1
178 48,xyyy 10.1
179 germ cells tumors 10.1
180 b-cell non-hodgkin lymphoma 10.1
181 rare hereditary hemochromatosis 10.1
182 systemic lupus erythematosus 10.1
183 thrombophilia due to thrombin defect 10.1
184 castleman disease 10.1
185 hypothyroidism 10.1
186 pneumothorax 10.1
187 bilirubin metabolic disorder 10.1
188 t-cell adult acute lymphocytic leukemia 10.1
189 pemphigus 10.1
190 engraftment syndrome 10.1
191 breast cancer 10.0
192 neurofibromatosis, type iv, of riccardi 10.0
193 down syndrome 10.0
194 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
195 wilms tumor 5 10.0
196 helix syndrome 10.0
197 thalassemia 10.0
198 sarcoma 10.0
199 lactic acidosis 10.0
200 hypokalemia 10.0
201 kidney disease 10.0
202 lung disease 10.0
203 toxoplasmosis 10.0
204 refractory anemia with excess blasts in transformation 10.0
205 kaposi sarcoma 10.0
206 hepatitis c virus 10.0
207 trichosporonosis 10.0
208 inflammatory bowel disease 10.0
209 tetanus 10.0
210 pneumocystosis 10.0
211 pulmonary edema 10.0
212 cryptococcosis 10.0
213 cellulitis 10.0
214 systemic mastocytosis 10.0
215 hepatitis e 10.0
216 neuroblastoma 10.0
217 ileus 10.0
218 influenza 10.0
219 herpes zoster 10.0
220 bacterial pneumonia 10.0
221 pulmonary embolism 10.0
222 acute non lymphoblastic leukemia 10.0
223 myelodysplastic syndrome with excess blasts 10.0
224 acute liver failure 10.0
225 diffuse large b-cell lymphoma 10.0
226 neutropenia 10.0
227 langerhans cell histiocytosis 10.0
228 splenic marginal zone lymphoma 10.0
229 endocarditis 10.0
230 viral pneumonia 10.0
231 strongyloidiasis 10.0
232 iron deficiency anemia 10.0
233 nephrotic syndrome 10.0
234 allergic hypersensitivity disease 10.0
235 pulmonary alveolar proteinosis 10.0
236 leukostasis 10.0
237 capillary leak syndrome 10.0
238 cholecystitis 10.0
239 hepatitis 10.0
240 iron metabolism disease 10.0
241 dermatitis 10.0
242 idiopathic interstitial pneumonia 10.0
243 bronchiolitis obliterans 10.0
244 hemoglobinopathy 10.0
245 bronchiolitis 10.0
246 lipid metabolism disorder 10.0
247 purpura 10.0
248 liver disease 10.0
249 infertility 10.0
250 acquired immunodeficiency syndrome 10.0
251 cataract 10.0
252 appendicitis 10.0
253 lupus erythematosus 10.0
254 candida glabrata 10.0
255 dendritic cell tumor 10.0
256 primary central nervous system lymphoma 10.0
257 t-cell non-hodgkin lymphoma 10.0
258 paraneoplastic pemphigus 10.0
259 diffuse alveolar hemorrhage 10.0
260 aspergillosis 10.0
261 follicular lymphoma 10.0
262 beta-thalassemia 9.9
263 erythroleukemia, familial 9.9
264 ovarian cancer 9.9
265 anemia, autoimmune hemolytic 9.9
266 ocular motor apraxia 9.9
267 osteogenic sarcoma 9.9
268 scott syndrome 9.9
269 hypophosphatemia 9.9
270 hyperphosphatemia 9.9
271 paroxysmal nocturnal hemoglobinuria 9.9
272 bone resorption disease 9.9
273 adult respiratory distress syndrome 9.9
274 hemopericardium 9.9
275 pericardial effusion 9.9
276 esophagitis 9.9
277 respiratory syncytial virus infectious disease 9.9
278 acute cystitis 9.9
279 cholestasis 9.9
280 eclampsia 9.9
281 oral candidiasis 9.9
282 squamous cell carcinoma 9.9
283 viral hepatitis 9.9
284 opportunistic mycosis 9.9
285 sensory peripheral neuropathy 9.9
286 cryoglobulinemia 9.9
287 skin disease 9.9
288 lynch syndrome 9.9
289 pyoderma 9.9
290 spindle cell sarcoma 9.9
291 hemoglobinuria 9.9
292 progressive multifocal leukoencephalopathy 9.9
293 end stage renal failure 9.9
294 pyoderma gangrenosum 9.9
295 crohn's disease 9.9
296 encephalitis 9.9
297 hypoglycemia 9.9
298 hemophilia 9.9
299 acute myeloblastic leukemia without maturation 9.9
300 glioma 9.9
301 t-cell prolymphocytic leukemia 9.9
302 glial tumor 9.9
303 secondary pulmonary alveolar proteinosis 9.9
304 methotrexate toxicity 9.9
305 pik3ca-related overgrowth syndrome 9.9
306 graft-versus-host disease 9.9
307 invasive aspergillosis 9.9
308 acute graft versus host disease 9.9
309 hemoglobin c disease 9.9
310 atrial standstill 1 9.8
311 cardiac arrhythmia 9.8
312 factor viii deficiency 9.8
313 hypercalcemia, infantile, 1 9.8
314 hypertriglyceridemia, familial 9.8
315 mastocytosis, cutaneous 9.8
316 muir-torre syndrome 9.8
317 myositis 9.8
318 neurofibromatosis, type i 9.8
319 noonan syndrome 1 9.8
320 rheumatoid arthritis 9.8
321 thrombocytopenic purpura, autoimmune 9.8
322 thrombophilia due to activated protein c resistance 9.8
323 lung cancer 9.8
324 hemochromatosis, type 1 9.8
325 proteasome-associated autoinflammatory syndrome 1 9.8
326 rhabdomyosarcoma 2 9.8
327 xeroderma pigmentosum, variant type 9.8
328 hemophilia a 9.8
329 ataxia and polyneuropathy, adult-onset 9.8
330 kala-azar 1 9.8
331 human immunodeficiency virus type 1 9.8
332 diabetes mellitus, ketosis-prone 9.8
333 lung cancer susceptibility 3 9.8
334 bacteremia 2 9.8
335 bacterial sepsis 9.8
336 cryptogenic organizing pneumonia 9.8
337 small cell carcinoma 9.8
338 t-cell large granular lymphocyte leukemia 9.8
339 sexual disorder 9.8
340 crohn's colitis 9.8
341 bone disease 9.8
342 angioimmunoblastic t-cell lymphoma 9.8
343 multicentric castleman disease 9.8
344 pre-eclampsia 9.8
345 portal hypertension 9.8
346 lipoid nephrosis 9.8
347 von willebrand's disease 9.8
348 hemolytic-uremic syndrome 9.8
349 coccidioidomycosis 9.8
350 beriberi 9.8
351 lymphadenitis 9.8
352 cryptosporidiosis 9.8
353 melanoma 9.8
354 leiomyosarcoma 9.8
355 gastroenteritis 9.8
356 thrombophilia 9.8
357 splenic infarction 9.8
358 geotrichosis 9.8
359 glucosephosphate dehydrogenase deficiency 9.8
360 glioblastoma multiforme 9.8
361 central nervous system disease 9.8
362 liposarcoma 9.8
363 pulmonary fibrosis 9.8
364 granuloma annulare 9.8
365 pleural empyema 9.8
366 arthropathy 9.8
367 gastritis 9.8
368 poliomyelitis 9.8
369 adult acute lymphocytic leukemia 9.8
370 bronchitis 9.8
371 hypersplenism 9.8
372 chronic kidney disease 9.8
373 myocarditis 9.8
374 peritonitis 9.8
375 paralytic ileus 9.8
376 ulcerative colitis 9.8
377 chronic monocytic leukemia 9.8
378 nervous system disease 9.8
379 hodgkin's lymphoma, mixed cellularity 9.8
380 pyomyositis 9.8
381 rubella 9.8
382 hodgkin's lymphoma, nodular sclerosis 9.8
383 leishmaniasis 9.8
384 plasma cell leukemia 9.8
385 bronchiectasis 9.8
386 fasciitis 9.8
387 necrotizing fasciitis 9.8
388 hemorrhoid 9.8
389 sickle cell disease 9.8
390 acquired hemophilia 9.8
391 blastic plasmacytoid dendritic cell 9.8
392 fournier gangrene 9.8
393 haemophilus influenzae 9.8
394 hhv-6 encephalitis 9.8
395 limbic encephalitis 9.8
396 marek disease 9.8
397 pseudo-turner syndrome 9.8
398 tetraploidy 9.8
399 dysphagia 9.8
400 headache 9.8
401 rapidly involuting congenital hemangioma 9.8
402 inflammatory myopathy with abundant macrophages 9.8
403 trisomy 1q 9.8
404 complications after hematopoietic stem cell transplantation 9.8
405 mantle cell lymphoma 9.8
406 basal cell carcinoma 9.8
407 adjustment disorder 9.8
408 chromosomal triplication 9.8
409 thyroid carcinoma 9.8
410 sclerosing liposarcoma 9.8
411 pfeiffer syndrome 9.7
412 metaphyseal chondrodysplasia, schmid type 9.7
413 meningioma, radiation-induced 9.7
414 meningioma, familial 9.7
415 neutrophilic dermatosis, acute febrile 9.7
416 spinal meningioma 9.7
417 obstructive jaundice 9.7
418 hemangioma 9.7
419 glomerulonephritis 9.7
420 embryonal carcinoma 9.7
421 cutaneous fibrous histiocytoma 9.7
422 benign meningioma 9.7
423 secretory meningioma 9.7
424 lymphoplasmacyte-rich meningioma 9.7
425 histiocytoid hemangioma 9.7
426 lymphoepithelioma-like carcinoma 9.7
427 epithelioid sarcoma 9.7
428 kimura disease 9.7
429 hydroa vacciniforme 9.7
430 posttransplant acute limbic encephalitis 9.7
431 hydroa vacciniforme-like lymphoma 9.7
432 alk-negative anaplastic large cell lymphoma 9.7
433 acute mast cell leukemia 9.7
434 esophageal cancer 9.7
435 felty syndrome 9.7
436 familial mediterranean fever 9.7
437 stomatin-like protein-2, hyperphosphorylation of 9.7
438 t-cell lymphoma, subcutaneous panniculitis-like 9.7
439 bladder sarcoma 9.7
440 panniculitis 9.7
441 breast fibroadenoma 9.7
442 syringoma 9.7
443 ring chromosome 9.7
444 alk-positive anaplastic large cell lymphoma 9.7
445 discoid lupus erythematosus 9.7
446 autoinflammatory syndrome 9.7
447 neurofibromatosis, type ii 9.7
448 alcohol dependence 9.7
449 alzheimer disease 9.7
450 spondyloarthropathy 1 9.7
451 leukemia, chronic lymphocytic 2 9.7
452 behcet syndrome 9.7
453 hepatocellular carcinoma 9.7
454 cryoglobulinemia, familial mixed 9.7
455 fibrosis of extraocular muscles, congenital, 1 9.7
456 lymphoma, mucosa-associated lymphoid type 9.7
457 gilbert syndrome 9.7
458 endosteal hyperostosis, autosomal dominant 9.7
459 ige responsiveness, atopic 9.7
460 mesothelioma, malignant 9.7
461 motion sickness 9.7
462 ataxia-pancytopenia syndrome 9.7
463 osteoporosis 9.7
464 pemphigus vulgaris, familial 9.7
465 polykaryocytosis inducer 9.7
466 porphyria cutanea tarda, type i 9.7
467 porphyria cutanea tarda 9.7
468 dowling-degos disease 1 9.7
469 schistosoma mansoni infection, susceptibility/ 9.7
470 scleroderma, familial progressive 9.7
471 smith-magenis syndrome 9.7
472 thyroid cancer, nonmedullary, 1 9.7
473 tuberous sclerosis 1 9.7
474 ataxia-telangiectasia 9.7
475 bloom syndrome 9.7
476 basal ganglia calcification, idiopathic, 1 9.7
477 costello syndrome 9.7
478 cryptorchidism, unilateral or bilateral 9.7
479 nijmegen breakage syndrome 9.7
480 nonarteritic anterior ischemic optic neuropathy 9.7
481 reticulum cell sarcoma 9.7
482 schinzel-giedion midface retraction syndrome 9.7
483 sjogren syndrome 9.7
484 thymoma, familial 9.7
485 sarcoma, synovial 9.7
486 anemia, nonspherocytic hemolytic, due to g6pd deficiency 9.7
487 premature ovarian failure 1 9.7
488 aging 9.7
489 retinitis pigmentosa 11 9.7
490 budd-chiari syndrome 9.7
491 autoimmune lymphoproliferative syndrome 9.7
492 ventricular fibrillation, paroxysmal familial, 1 9.7
493 cervical cancer 9.7
494 alpha-thalassemia 9.7
495 ascaris lumbricoides infection 9.7
496 rheumatoid arthritis, systemic juvenile 9.7
497 creatinine clearance quantitative trait locus 9.7
498 allergic rhinitis 9.7
499 mycobacterium tuberculosis 1 9.7
500 endometrial cancer 9.7
501 autoimmune disease 3 9.7
502 myocardial infarction 9.7
503 major depressive disorder 9.7
504 colorectal cancer, hereditary nonpolyposis, type 2 9.7
505 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.7
506 malaria 9.7
507 legius syndrome 9.7
508 intraocular pressure quantitative trait locus 9.7
509 bone mineral density quantitative trait locus 8 9.7
510 ewing sarcoma 9.7
511 microvascular complications of diabetes 5 9.7
512 hypotrichosis and recurrent skin vesicles 9.7
513 fatty liver disease, nonalcoholic 1 9.7
514 bone mineral density quantitative trait locus 15 9.7
515 chromosome 8p11 myeloproliferative syndrome 9.7
516 barrett esophagus 9.7
517 dengue virus 9.7
518 membranous nephropathy 9.7
519 schuurs-hoeijmakers syndrome 9.7
520 alacrima, achalasia, and mental retardation syndrome 9.7
521 tatton-brown-rahman syndrome 9.7
522 glucocorticoid resistance, generalized 9.7
523 b-cell expansion with nfkb and t-cell anergy 9.7
524 cataract 44 9.7
525 au-kline syndrome 9.7
526 hydrops, lactic acidosis, and sideroblastic anemia 9.7
527 mirage syndrome 9.7
528 rahman syndrome 9.7
529 diarrhea 9 9.7
530 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
531 hepatitis, fulminant viral 9.7
532 peripheral vascular disease 9.7
533 angina pectoris 9.7
534 angiosarcoma 9.7
535 sulfonamide allergy 9.7
536 secretory diarrhea 9.7
537 pulmonary aspergilloma 9.7
538 erythema multiforme 9.7
539 familial adenomatous polyposis 9.7
540 restless legs syndrome 9.7
541 loeys-dietz syndrome 9.7
542 autosomal recessive disease 9.7
543 metabolic acidosis 9.7
544 limb ischemia 9.7
545 inflammatory myofibroblastic tumor 9.7
546 ovarian clear cell carcinoma 9.7
547 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.7
548 colitis 9.7
549 ptosis 9.7
550 beta-lactam allergy 9.7
551 waldenstroem's macroglobulinemia 9.7
552 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.7
553 relapsed/refractory diffuse large b-cell lymphoma 9.7
554 nodal marginal zone lymphoma 9.7
555 endometrial hyperplasia 9.7
556 coronavirus infection 9.7
557 hypogonadotropic hypogonadism 9.7
558 acquired von willebrand syndrome 9.7
559 asymptomatic neurosyphilis 9.7
560 cysticercosis 9.7
561 xerophthalmia 9.7
562 osteomyelitis 9.7
563 dermatomyositis 9.7
564 ehrlichiosis 9.7
565 aggressive nk-cell leukemia 9.7
566 gastric lymphoma 9.7
567 rickets 9.7
568 thrombotic thrombocytopenic purpura 9.7
569 methemoglobinemia 9.7
570 hemiplegia 9.7
571 brucellosis 9.7
572 hydronephrosis 9.7
573 pertussis 9.7
574 vitamin k deficiency bleeding 9.7
575 microcytic anemia 9.7
576 pyelonephritis 9.7
577 cardiac tamponade 9.7
578 listeriosis 9.7
579 cauda equina syndrome 9.7
580 infant gynecomastia 9.7
581 lyme disease 9.7
582 visual epilepsy 9.7
583 mononeuropathy 9.7
584 inflammatory spondylopathy 9.7
585 primary biliary cirrhosis 9.7
586 testicular lymphoma 9.7
587 retroperitoneal lymphoma 9.7
588 graves' disease 9.7
589 dysentery 9.7
590 hepatitis a 9.7
591 hepatic coma 9.7
592 blastomycosis 9.7
593 gynecomastia 9.7
594 telangiectasis 9.7
595 quadriplegia 9.7
596 keratoconjunctivitis sicca 9.7
597 hereditary spherocytosis 9.7
598 balanoposthitis 9.7
599 relapsing fever 9.7
600 paronychia 9.7
601 focal segmental glomerulosclerosis 9.7
602 severe pre-eclampsia 9.7
603 fungal esophagitis 9.7
604 gout 9.7
605 brain cancer 9.7
606 pneumatosis cystoides intestinalis 9.7
607 porphyria 9.7
608 klebsiella pneumonia 9.7
609 hepatic encephalopathy 9.7
610 urethritis 9.7
611 tuberous sclerosis 9.7
612 amenorrhea 9.7
613 schistosomiasis 9.7
614 poems syndrome 9.7
615 plasmodium falciparum malaria 9.7
616 gonadal dysgenesis 9.7
617 pleural disease 9.7
618 urticaria 9.7
619 thrombocytopenia due to platelet alloimmunization 9.7
620 mental depression 9.7
621 histoplasmosis 9.7
622 vascular disease 9.7
623 neuroendocrine carcinoma 9.7
624 optic nerve disease 9.7
625 hypogonadism 9.7
626 giant cell tumor 9.7
627 pharyngitis 9.7
628 hidradenitis suppurativa 9.7
629 hidradenitis 9.7
630 keratopathy 9.7
631 colon adenocarcinoma 9.7
632 polyclonal hypergammaglobulinemia 9.7
633 macrocytic anemia 9.7
634 motor peripheral neuropathy 9.7
635 relapsing polychondritis 9.7
636 transitional cell carcinoma 9.7
637 acalculous cholecystitis 9.7
638 endometrial adenocarcinoma 9.7
639 newcastle disease 9.7
640 severe acute respiratory syndrome 9.7
641 pulmonary tuberculosis 9.7
642 adenocarcinoma 9.7
643 germ cell cancer 9.7
644 interstitial lung disease 9.7
645 ascaridiasis 9.7
646 skin squamous cell carcinoma 9.7
647 lipomatosis 9.7
648 neurilemmoma 9.7
649 chronic granulomatous disease 9.7
650 thymoma 9.7
651 vaccinia 9.7
652 teratocarcinoma 9.7
653 teratoma 9.7
654 mesenchymal cell neoplasm 9.7
655 fibrosarcoma 9.7
656 chondroblastic osteosarcoma 9.7
657 cerebritis 9.7
658 skin carcinoma 9.7
659 turner syndrome 9.7
660 signet ring cell adenocarcinoma 9.7
661 cavernous sinus thrombosis 9.7
662 aortic aneurysm 9.7
663 gastric adenocarcinoma 9.7
664 extramedullary plasmacytoma 9.7
665 cervical squamous cell carcinoma 9.7
666 colonic pseudo-obstruction 9.7
667 adrenal carcinoma 9.7
668 merkel cell carcinoma 9.7
669 thyroid gland papillary carcinoma 9.7
670 spindle cell carcinoma 9.7
671 granulomatous dermatitis 9.7
672 endophthalmitis 9.7
673 embryoma 9.7
674 sebaceous adenocarcinoma 9.7
675 thyroid gland disease 9.7
676 liver cirrhosis 9.7
677 ovarian cyst 9.7
678 urinary tract obstruction 9.7
679 gingival hypertrophy 9.7
680 hemoglobin d disease 9.7
681 mature teratoma 9.7
682 aortic valve insufficiency 9.7
683 pediatric lymphoma 9.7
684 paraplegia 9.7
685 conjunctivitis 9.7
686 combined t cell and b cell immunodeficiency 9.7
687 connective tissue disease 9.7
688 overnutrition 9.7
689 spondylitis 9.7
690 juvenile rheumatoid arthritis 9.7
691 lung lymphoma 9.7
692 mediastinal malignant lymphoma 9.7
693 precursor b lymphoblastic lymphoma/leukemia 9.7
694 thyroiditis 9.7
695 hypogonadotropism 9.7
696 gastrointestinal system disease 9.7
697 hyperthyroidism 9.7
698 periodontitis 9.7
699 arthritis 9.7
700 bullous pemphigoid 9.7
701 reticulosarcoma 9.7
702 perinatal necrotizing enterocolitis 9.7
703 intermediate coronary syndrome 9.7
704 chorioretinitis 9.7
705 skin melanoma 9.7
706 gas gangrene 9.7
707 mast-cell leukemia 9.7
708 priapism 9.7
709 viral infectious disease 9.7
710 acute myocardial infarction 9.7
711 intracranial hypertension 9.7
712 meningitis 9.7
713 pathologic nystagmus 9.7
714 placental abruption 9.7
715 miliary tuberculosis 9.7
716 follicular mucinosis 9.7
717 steroid-induced glaucoma 9.7
718 ltbp4-related cutis laxa 9.7
719 1q duplications 9.7
720 47, xxy 9.7
721 acquired hemophilia a 9.7
722 acute erythroid leukemia 9.7
723 acute leukemia of ambiguous lineage 9.7
724 anca-associated vasculitis 9.7
725 antisynthetase syndrome 9.7
726 chromosome 9 inversion 9.7
727 clostridium septicum infection 9.7
728 cold agglutinin disease 9.7
729 congenital cytomegalovirus 9.7
730 growth hormone deficiency 9.7
731 human t-cell leukemia virus type 1 9.7
732 indolent b cell lymphoma 9.7
733 laryngocele 9.7
734 light chain deposition disease 9.7
735 lymphomatoid granulomatosis 9.7
736 mthfr gene variant 9.7
737 neurosyphilis 9.7
738 oral cancer 9.7
739 pemphigus foliaceus 9.7
740 plasmablastic lymphoma 9.7
741 polymyositis 9.7
742 pure autonomic failure 9.7
743 rosai-dorfman disease 9.7
744 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
745 systemic onset juvenile idiopathic arthritis 9.7
746 triploidy 9.7
747 wells syndrome 9.7
748 dnmt3a overgrowth syndrome 9.7
749 pacs1 syndrome 9.7
750 depression 9.7
751 hypoxia 9.7
752 seizure disorder 9.7
753 tremor 9.7
754 systemic autoimmune disease 9.7
755 secondary hemophagocytic lymphohistiocytosis 9.7
756 partial deletion of chromosome 9 9.7
757 virus-associated trichodysplasia spinulosa 9.7
758 autoimmune hemolytic anemia, cold type 9.7
759 acute sensory ataxic neuropathy 9.7
760 argyria 9.7
761 bullous pyoderma gangrenosum 9.7
762 hepatosplenic t-cell lymphoma 9.7
763 coronary sinus atresia 9.7
764 primary mediastinal large b-cell lymphoma 9.7
765 acute myeloid leukemia with minimal differentiation 9.7
766 intravascular large b-cell lymphoma 9.7
767 pachyonychia congenita 3 9.7
768 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
769 female breast cancer 9.7
770 berylliosis 9.7
771 seminoma 9.7
772 peptic ulcer disease 9.7
773 alopecia areata 9.7
774 familial episodic pain syndrome 9.7
775 medulloblastoma 9.6
776 li-fraumeni syndrome 9.6
777 hypercholesterolemia, familial, 1 9.6
778 burkitt lymphoma 9.6
779 gaucher disease, type i 9.6
780 pancreatic cancer 9.6
781 pleuropulmonary blastoma 9.6
782 anxiety 9.6
783 li-fraumeni syndrome 2 9.6
784 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
785 human herpesvirus 8 9.6
786 adrenal cortical carcinoma 9.6
787 dengue shock syndrome 9.6
788 anaplastic large cell lymphoma 9.6
789 lymphoplasmacytic lymphoma 9.6
790 paraganglioma 9.6
791 hemorrhagic cystitis 9.6
792 cardiac arrest 9.6
793 thrombosis 9.6
794 childhood acute lymphocytic leukemia 9.6
795 lymphoblastic lymphoma 9.6
796 osteonecrosis 9.6
797 mumps 9.6
798 prolymphocytic leukemia 9.6
799 respiratory failure 9.6
800 disseminated intravascular coagulation 9.6
801 diphtheria 9.6
802 diarrhea 9.6
803 polyneuropathy 9.6
804 toxic shock syndrome 9.6
805 generalized anxiety disorder 9.6
806 cystitis 9.6
807 gaucher's disease 9.6
808 agammaglobulinemia 9.6
809 kidney cancer 9.6
810 benign mesothelioma 9.6
811 rhabdomyosarcoma 9.6
812 mood disorder 9.6
813 plasmacytoma 9.6
814 hyperglycemia 9.6
815 pustulosis of palm and sole 9.6
816 plasma cell neoplasm 9.6
817 adenoma 9.6
818 malignant histiocytosis 9.6
819 measles 9.6
820 subacute delirium 9.6
821 vasculitis 9.6
822 in situ carcinoma 9.6
823 psoriasis 9.6
824 macroglobulinemia 9.6
825 dicer1-related disorders 9.6
826 chronic graft versus host disease 9.6
827 dicer1-related pleuropulmonary blastoma cancer predisposition syndrome 9.6
828 homologous wasting disease 9.6
829 lymphoma aids related 9.6
830 lymphosarcoma 9.6
831 post-transplant lymphoproliferative disease 9.6
832 multiple endocrine neoplasia 9.6
833 histiocytic sarcoma 9.6
834 thrombotic microangiopathy 9.6
835 overgrowth syndrome 9.6
836 gallbladder disease 1 9.6
837 sickle cell anemia 9.6
838 hemoglobin h disease 9.6
839 pulmonary hypertension 9.6
840 thymus lymphoma 9.6
841 malignant glioma 9.6
842 solitary osseous plasmacytoma 9.6
843 cutaneous mastocytoma 9.6
844 plasma cell tumor 9.6
845 yemenite deaf-blind hypopigmentation syndrome 9.6
846 cortical blindness 9.6
847 paresthesia 9.6
848 sarcoidosis 1 9.5
849 colorectal cancer 9.5
850 bladder cancer 9.5
851 enterocolitis 9.5
852 body mass index quantitative trait locus 1 9.5
853 granulomatosis with polyangiitis 9.5
854 pollen allergy 9.5
855 igg4-related disease 9.5
856 bacterial infectious disease 9.5
857 heart disease 9.5
858 sphingolipidosis 9.5
859 hepatitis b 9.5
860 tic disorder 9.5
861 substance abuse 9.5
862 lysosomal storage disease 9.5
863 embryonal rhabdomyosarcoma 9.5
864 histiocytosis 9.5
865 clear cell sarcoma 9.5
866 juvenile xanthogranuloma 9.5
867 congestive heart failure 9.5
868 hard palate cancer 9.5
869 rare tumor 9.5

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer
Sources

Symptoms & Phenotypes for Hematologic Cancer

About this section

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26 (showing 3, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

45 (showing 8, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ABL1 CBL ETV6 FLT3 IL2 JAK2
2 growth/size/body region MP:0005378 10.15 ABL1 CBL ETV6 FLT3 IL2 JAK2
3 hematopoietic system MP:0005397 10.13 ABL1 CBL CSF3 ETV6 FLT3 IL2
4 immune system MP:0005387 10.07 ABL1 CBL CSF3 ETV6 FLT3 IL2
5 endocrine/exocrine gland MP:0005379 10.06 ABL1 CBL ETV6 FLT3 IL2 JAK2
6 liver/biliary system MP:0005370 9.76 ABL1 CBL IL2 JAK2 KIT KMT2A
7 neoplasm MP:0002006 9.56 ETV6 FLT3 IL2 JAK2 KIT KMT2A
8 respiratory system MP:0005388 9.17 ABL1 CBL IL2 JAK2 KIT PTHLH
Sources

Drugs & Therapeutics for Hematologic Cancer

About this section

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 528, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
2
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
3
Voriconazole Approved Phase 4 137234-62-9 71616
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Protein C Approved Phase 4
7
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
8
Busulfan Approved, Investigational Phase 4 55-98-1 2478
9
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
10 Daratumumab Approved Phase 4 945721-28-8
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Glucagon Approved Phase 4 16941-32-5
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
17
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
18
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
19 Lactams Phase 4
20 beta-Lactams Phase 4
21 penicillins Phase 4
22 Epoetin alfa Phase 4 113427-24-0
23 Drotrecogin alfa activated Phase 4
24 Thymoglobulin Phase 4
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Incretins Phase 4
30 Hypoglycemic Agents Phase 4
31 Glucagon-Like Peptide 1 Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Antiparasitic Agents Phase 4
34 Antiprotozoal Agents Phase 4
35 Pharmaceutical Solutions Phase 4
36 Cytochrome P-450 CYP3A Inhibitors Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Steroid Synthesis Inhibitors Phase 4
39 Liposomal amphotericin B Phase 4
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
41
Hydroxyitraconazole Phase 4
42
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
43
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
44
Piperacillin Approved Phase 3 66258-76-2 43672
45
Tazobactam Approved Phase 3 89786-04-9 123630
46
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
47
Denosumab Approved Phase 3 615258-40-7
48
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
49
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
50
Febuxostat Approved Phase 3 144060-53-7 134018
51
deoxycholic acid Approved Phase 3 83-44-3 222528
52
Vancomycin Approved Phase 3 1404-90-6 441141 14969
53
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
54
Micafungin Approved, Investigational Phase 3 235114-32-6 3081921 477468
55
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
56
Tranexamic Acid Approved Phase 3 1197-18-8 5526
57
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
58 Vedolizumab Approved Phase 3 943609-66-3
59
Imipenem Approved Phase 2, Phase 3 64221-86-9, 74431-23-5 104838
60
Cilastatin Approved, Investigational Phase 2, Phase 3 82009-34-5 5280454 6435415
61
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
62
Fosaprepitant Approved Phase 3 172673-20-0 219090
63
Aprepitant Approved, Investigational Phase 3 170729-80-3 151165 6918365
64
Nitrous oxide Approved, Vet_approved Phase 2, Phase 3 10024-97-2 948
65
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
66
Daunorubicin Approved Phase 3 20830-81-3 30323
67
tannic acid Approved Phase 3 1401-55-4
68
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
69
Lenalidomide Approved Phase 3 191732-72-6 216326
70
Peginterferon alfa-2b Approved Phase 2, Phase 3 215647-85-1, 99210-65-8
71
Sodium citrate Approved, Investigational Phase 3 68-04-2
72
Idarubicin Approved Phase 3 58957-92-9 42890
73
leucovorin Approved Phase 3 58-05-9 6006 143
74
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
75
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
76
Fluorouracil Approved Phase 3 51-21-8 3385
77
Zoledronic Acid Approved Phase 3 118072-93-8 68740
78
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
79
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793